| 1 |
Kang H, Miksche MS, Ellingsen DM. Association between personality traits and placebo effects: a preregistered systematic review and meta-analysis. Pain 2023;164:494-508. [PMID: 35947877 DOI: 10.1097/j.pain.0000000000002753] [Reference Citation Analysis]
|
| 2 |
Chang L, Cash BD, Lembo A, Kunkel DC, English BA, Lindstrom B, Gu G, Skare S, Gilder K, Turner S, Cataldi F, Lipkis D, Jan T. Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE). Neurogastroenterol Motil 2023;:e14539. [PMID: 36740814 DOI: 10.1111/nmo.14539] [Reference Citation Analysis]
|
| 3 |
Bosman M, Smeets F, Elsenbruch S, Tack J, Simrén M, Talley N, Winkens B, Masclee A, Keszthelyi D. Placebo response in pharmacological trials in patients with functional dyspepsia-A systematic review and meta-analysis. Neurogastroenterol Motil 2023;35:e14474. [PMID: 36168188 DOI: 10.1111/nmo.14474] [Reference Citation Analysis]
|
| 4 |
Quigley EMM, Markinson L, Stevenson A, Treasure FP, Lacy BE. Randomised clinical trial: efficacy and safety of the live biotherapeutic product MRx1234 in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2023;57:81-93. [PMID: 36369645 DOI: 10.1111/apt.17310] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 5 |
Lembo A, Kuo B, Boinpally R, Li E, Mallick M, Bochenek W, Bartolini W. Randomised clinical trial: effects of MD-7246 on irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther 2023;57:192-204. [PMID: 36324245 DOI: 10.1111/apt.17274] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 6 |
Hohenschurz-Schmidt D, Thomson OP, Rossettini G, Miciak M, Newell D, Roberts L, Vase L, Draper-Rodi J. Avoiding nocebo and other undesirable effects in chiropractic, osteopathy and physiotherapy: An invitation to reflect. Musculoskelet Sci Pract 2022;62:102677. [PMID: 36368170 DOI: 10.1016/j.msksp.2022.102677] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 7 |
Rej A, Sanders DS, Shaw CC, Buckle R, Trott N, Agrawal A, Aziz I. Efficacy and Acceptability of Dietary Therapies in Non-Constipated Irritable Bowel Syndrome: A Randomized Trial of Traditional Dietary Advice, the Low FODMAP Diet, and the Gluten-Free Diet. Clin Gastroenterol Hepatol 2022;20:2876-2887.e15. [PMID: 35240330 DOI: 10.1016/j.cgh.2022.02.045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 8 |
Qi LY, Yang JW, Yan SY, Tu JF, She YF, Li Y, Chi LL, Wu BQ, Liu CZ. Acupuncture for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Randomized Clinical Trial. JAMA Netw Open 2022;5:e2248817. [PMID: 36580333 DOI: 10.1001/jamanetworkopen.2022.48817] [Reference Citation Analysis]
|
| 9 |
Wise JL, Ingrosso MR, Ianiro G, Black CJ, Ford AC, Lacy BE. Response and Adverse Event Rates With Placebo in Gastroparesis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00969-7. [PMID: 36270614 DOI: 10.1016/j.cgh.2022.09.033] [Reference Citation Analysis]
|
| 10 |
Rej A, Avery A, Aziz I, Black CJ, Bowyer RK, Buckle RL, Seamark L, Shaw CC, Thompson J, Trott N, Williams M, Sanders DS. Diet and irritable bowel syndrome: an update from a UK consensus meeting. BMC Med 2022;20:287. [PMID: 36096789 DOI: 10.1186/s12916-022-02496-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
van der Schoot A, Drysdale C, Whelan K, Dimidi E. The Effect of Fiber Supplementation on Chronic Constipation in Adults: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Clin Nutr 2022;116:953-69. [PMID: 35816465 DOI: 10.1093/ajcn/nqac184] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 12 |
Pimentel M, Mathur R, Wang J, Chang C, Hosseini A, Fiorentino A, Rashid M, Pichetshote N, Basseri B, Treyzon L, Chang B, Leite G, Morales W, Weitsman S, Kraus A, Rezaie A. A Smartphone Application Using Artificial Intelligence Is Superior To Subject Self-Reporting When Assessing Stool Form. Am J Gastroenterol 2022;117:1118-24. [PMID: 35288511 DOI: 10.14309/ajg.0000000000001723] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Huang H, Lu L, Chen Y, Zeng Y, Xu C. The efficacy of vitamin D supplementation for irritable bowel syndrome: a systematic review with meta-analysis. Nutr J 2022;21:24. [PMID: 35509010 DOI: 10.1186/s12937-022-00777-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 14 |
Barberio B, Savarino EV, Black CJ, Ford AC. Placebo Response Rates in Trials of Licensed Drugs for Irritable Bowel Syndrome With Constipation or Diarrhea: Meta-analysis. Clin Gastroenterol Hepatol 2022;20:e923-44. [PMID: 34425274 DOI: 10.1016/j.cgh.2021.08.025] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 15 |
Wu J, Lv L, Wang C. Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials. Front Cell Infect Microbiol 2022;12:827395. [DOI: 10.3389/fcimb.2022.827395] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 16 |
Peng LH, Fang JY, Dai N, Shen XZ, Yang YL, Sun J, Yang YS. Efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation: Chinese sub-cohort analysis of a phase III, randomized, double-blind, placebo-controlled trial. J Dig Dis 2022;23:99-110. [PMID: 35019221 DOI: 10.1111/1751-2980.13081] [Reference Citation Analysis]
|
| 17 |
Lambarth A, Zarate-Lopez N, Fayaz A. Oral and parenteral anti-neuropathic agents for the management of pain and discomfort in irritable bowel syndrome: A systematic review and meta-analysis. Neurogastroenterol Motil 2022;34:e14289. [PMID: 34755926 DOI: 10.1111/nmo.14289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 18 |
Benson S, Theysohn N, Kleine-Borgmann J, Rebernik L, Icenhour A, Elsenbruch S. Positive Treatment Expectations Shape Perceived Medication Efficacy in a Translational Placebo Paradigm for the Gut-Brain Axis. Front Psychiatry 2022;13:824468. [PMID: 35401247 DOI: 10.3389/fpsyt.2022.824468] [Reference Citation Analysis]
|
| 19 |
Wechsler EV, Shah ED. Diarrhea-Predominant and Constipation-Predominant Irritable Bowel Syndrome: Current Prescription Drug Treatment Options. Drugs 2021;81:1953-68. [PMID: 34727333 DOI: 10.1007/s40265-021-01634-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 20 |
Melchior C, Nuzzo A, Keszthelyi D. How to raise the interest for neurogastroenterology among young gastroenterologists? United European Gastroenterol J 2021. [PMID: 34724358 DOI: 10.1002/ueg2.12174] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 21 |
Shah ED. Optimising clinical trial design to manage placebo response in randomised controlled trials of irritable bowel syndrome. Lancet Gastroenterol Hepatol 2021;6:416-7. [PMID: 33765446 DOI: 10.1016/S2468-1253(21)00056-X] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
